Podcasts about admp

ADMP de los tres primeros episodios de esta miniserie por razones de #Accesibilidad, ya que la Disney no ofrece la AD profesional en español, solo en inglés. Así que en vez de hacer la ADCD he decidido realizar una AudioDescripción Muy Personal de 'Shōgun' Capítulos 1-2-3.

Insider Financial recaps Tuesday's penny stock action, including the #1 NASDAQ penny stock that we released in the after-hours to our subscribers on Monday night. This video covers SPY, QQQ, FNGR, CGRA, PEGY, ILAG, ADMP, GEGI, META, and MSFT. To sign up for real-time alerts along with our FREE reports and eBook, go to: https://signup.insiderfinancial.com/ To sign up for FREE stocks and trade 4am to 8pm on WeBull, go to: https://a.webull.com/i/insiderfinancial Disclosure: We have no business relationship with any company whose stock is mentioned in this video. Insider Financial is not an investment advisor; this video does not provide investment advice. Always do your own research, make your own investment decisions, or consult with your nearest financial advisor. This video is not a solicitation or recommendation to buy, sell, or hold securities. This video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance. For more information, please read our full disclaimer:https://insiderfinancial.com/disclaimer/ spy etf, qqq etf, fngr stock, cgra stock, pegy stock, ilag stock, admp stock, gegi stock, meta stock, msft stock, otc stocks, otc stocks list, penny stocks, penny stocks list, NASDAQ penny stocks, NYSE stocks, NYSE penny stocks #pennystocks #pennystockstobuynow #pennystocks2022

El centro tecnológico IDEKO lidera el proyecto europeo INFINITE centrado en la instalación de sensores para monitorizar de por vida el estado de los materiales de los aviones. Gracias a estos sensores, será posible realizar un seguimiento durante todo el ciclo de vida de las estructuras aeronáuticas: desde la supervisión in situ de su fabricación, pasando por la reparación y revisión del servicio mediante el monitorización de su salud estructural, hasta el reciclaje de las piezas al final de su vida útil. Conversamos con Peio Olaskoaga, coordinador del proyecto INFINITE y responsable de ADMP en IDEKO

This episode is a round table discussion with the whole ADMP team on ghosts. Experiences, possible explanations, and a lot of skepticism because I, Jack, am a cynical asshole. As always, we hope you enjoy.

A year in review for the whole ADMP family. Join us as we partake in holiday festivities and try to remember things about all of our episodes. As always, we hope you enjoy

This is an experimental episode where we are going in without any research or even a topic and just talking about interesting morbid things. there are stories, there are statistics, and some of our jokes are almost not mediocre. As always we hope you enjoy.

It is the end of this god awful year of 2020 and we couldn't be more excited for the future. We decided as a thank you to all of our listeners as well as the voice of our intros (Constantine Bleys), we will do an episode on our most requested topic yet and bring the man himself back on the show to cover it. Learn about the facts and the myths about one of Eastern Europe's most ruthless nobles and how her terror has been an influence in fiction and pop culture for hundreds of years.  It has been one hell of a year and we are excited for what 2021 has to bring. From all of us here on ADMP, thank you for listening and showing us support, and as always, we hope you enjoy!

It is that special time of year where everyone is rude and people drive like assholes. Its cold and wet outside, expectations leave us full of anxiety, our wallets all take a huge hit, and everyone pretends to get along with each other because its the season of "giving" and "caring"  So come pour yourself a drink and join us as we dissect the history behind some of the customs associated with this holiday season. As always we hope you enjoy and Happy Holidays from all of us here in ADMP

Music composed & produced by Johan F. Langhendries aka's Wannislas / Johan Franz Lang, for Abstinent Dazzle Music Productions (ADMP). Unauthorized copying, reproduction, hiring, lending, public performance etc. © Copyright 2016. All rights reserved - ADMP, Belgium 2020.

Music composed & produced by Johan F. Langhendries aka's Wannislas / Johan Franz Lang, for Abstinent Dazzle Music Productions (ADMP). Unauthorized copying, reproduction, hiring, lending, public performance etc. © Copyright 2016. All rights reserved - ADMP, Belgium 2020.

Music composed & produced by Johan F. Langhendries aka's Wannislas / Johan Franz Lang, for Abstinent Dazzle Music Productions (ADMP). Unauthorized copying, reproduction, hiring, lending, public performance etc. © Copyright 2016. All rights reserved - ADMP, Belgium 2020.

Look, Mommy! Dinosaurs! Aw, hell yeah! This week, ADMP goes full Kaiju!! Is that a euphamism for something? Anyways, we start with Gareth Edwards 2014 reboot of Godzilla. Then, it's Guillermo Del Toro's turn with 2013's Pacific Rim. Wait, that HAS to be a euphamism for something... Right?

www.adamispharmaceuticals.com “Strong Buy” 12-month Price Target of $15 - $18 indicates a potential price gain of 224% to 269%* 22-page research report by Harbinger Research details Investment Opportunity, Valuation Comparables... includes Profit and Loss Models thru FY2022. Brian Connell, CFA Investment Highlights: Net $23.7 million in recent funding and NASDAQ up-listing constitutes “Major Corporate Milestones” – institutional and retail visibility greatly enhanced. First product (Epinephrine Pre-filled Syringe) ready for FDA 505(B)(2) filing soon - early ’15 approval likely, leading to $30 - $50 million in annual sales over next 2 – 3 years. Completed purchase of the 3M Taper Dry Powder Inhaler (DPI) technology in December 2013 – creating potential branded generic competitor for Glaxo-SmithKline (NYSE: GSK) and its $7.7 billion global market.  Two additional products will likely receive FDA approval in 2016 and 2017 - eventual annual revenues of $30 million or more expected for each. Revenues starting in FY2015, with rapid growth in FY2016, FY2017 and FY2018 - estimated at $16.75MM, $49.45MM and $93.12MM, respectively – all subject to FDA approvals and market conditions of course, but Adamis has certainly turned the corner as a “Developing Specialty Pharmaceuticals Co.” Four early stage biotech products focused on the treatment of prostate cancer - given that the Company’s current priority is “to get to market” with its specialty pharma products, the biotech segment could create a win-fall for investors through a spin-out, IPO, sale to a larger biotech firm, or through royalties/marketing partnerships. It’s like a free-call option for informed investors. Company Overview: Adamis is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. ADMP is developing low cost therapeutic alternatives for the treatment of anaphylaxis, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Within the Company's biotechnology pipeline is a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer. *Based on market close, March 19, 2014

www.adamispharmaceuticals.com “Strong Buy” 12-month Price Target of $15 - $18 indicates a potential price gain of 224% to 269%* 22-page research report by Harbinger Research details Investment Opportunity, Valuation Comparables... includes Profit and Loss Models thru FY2022. Brian Connell, CFA Investment Highlights: Net $23.7 million in recent funding and NASDAQ up-listing constitutes “Major Corporate Milestones” – institutional and retail visibility greatly enhanced. First product (Epinephrine Pre-filled Syringe) ready for FDA 505(B)(2) filing soon - early ’15 approval likely, leading to $30 - $50 million in annual sales over next 2 – 3 years. Completed purchase of the 3M Taper Dry Powder Inhaler (DPI) technology in December 2013 – creating potential branded generic competitor for Glaxo-SmithKline (NYSE: GSK) and its $7.7 billion global market.  Two additional products will likely receive FDA approval in 2016 and 2017 - eventual annual revenues of $30 million or more expected for each. Revenues starting in FY2015, with rapid growth in FY2016, FY2017 and FY2018 - estimated at $16.75MM, $49.45MM and $93.12MM, respectively – all subject to FDA approvals and market conditions of course, but Adamis has certainly turned the corner as a “Developing Specialty Pharmaceuticals Co.” Four early stage biotech products focused on the treatment of prostate cancer - given that the Company’s current priority is “to get to market” with its specialty pharma products, the biotech segment could create a win-fall for investors through a spin-out, IPO, sale to a larger biotech firm, or through royalties/marketing partnerships. It’s like a free-call option for informed investors. Company Overview: Adamis is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. ADMP is developing low cost therapeutic alternatives for the treatment of anaphylaxis, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Within the Company's biotechnology pipeline is a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer. *Based on market close, March 19, 2014

I distrust a close-mouthed man. He generally picks the wrong time to talk and says the wrong things. Talking's something you can't do judiciously, unless you keep in practice. This week it is all about the noir mysteries! We start with the 1941 Humphry Bogart film, THe Maltese Falcon, and then move into our first installment of our Polanski festival with Chinatown. Then, we get stupid with our top 5 movie hats. Vote for the 200 special and don't forget to call in! 707-408-ADMP

Man is not an animal. We are not a part of the animal kingdom. We sit far above that crown, perched as spirits, not beasts. I have unlocked and discovered a secret to living in these bodies that we hold. Indeed. This week, it's all about the charasmatic, frightening world of cults, religious movements and the people who lead them. We start with P.T. Anderson's 2012 film The Master, then finish off the You Should See This festival with the Fred Phelps Documentary, Fall From Grace. Finally, top five spiritual leaders. Be sure to call and leave us something for our 200th episode! 707-408-ADMP

Oh Grace, I think you have plenty to offer the town of Dogville. Some heavy stuff this week, folks! We start with trying to sift through the misery and mystery of Lars Von Triers experimental morality tale, Dogville. Then we get into the third installment of Palcher's You Should See This Festival, The Arbor. A 2010 documentary/experimental film about the life of british playwright Andrea Dunbar, and how her abuse and addiction affected the lives of her children. Then we get into our Top 5 unconventional films. Don't forget to call in and leave feedback for our 200th episode!! 1-707-408-ADMP (2367)